Search Results
Results found for "Beth Fleck"
- The Truth About GPCR Product Launches: Years in the Making
Every GPCR assay that makes it to market carries years of failures, late-night ideas, risky bets, and Built to Win: The IP One Gamble After the success of their cAMP assay, Trinquet’s team took a risky bet More importantly, it worked across formats: from overexpression systems to endogenous GPCRs in native beta
- How a Failed Med School Dream Sparked a GPCR Biotech Revolution
Lessons From the Front Lines of Biotech Ajay’s experience in both early-stage biotech and academic science
- Your GPCR Program Decisions Depend on Good Data Interpretation
Katerina Leftheris : New technologies overcoming peptide limitations with insights from both pharma and
- When January Looks Different by March: Orthosteric vs. Allosteric Insights from Our Latest AMA
Probe dependence reveals hidden selectivity and efficacy shifts It becomes critical in both screening
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
The model’s flexibility accommodates both agonism and antagonism as long as the analysis targets equilibrium
- Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies
Both orphan and well-characterized GPCRs are untapped opportunities for drug development targeting CNS
- Why Opposing Processes Matter for Your Next GPCR Drug
Dobutamine’s dual action on beta and alpha receptors, for example, invites reflex bradycardia that blunts
- Mechanism vs. Assumption: A Model-First Path to Getting GPCR MoA Right
localization, trafficking, and dynamics—if your probes preserve function, minimize phototoxicity, and work in both
- Neuronal Gα subunits required for the control of response to polystyrene nanoparticles in the ...
Caenorhabditis elegans was used as an animal model, and both gene expression and functional analysis
- Fentanyl and Xylazine: Why Breathing Fails in Overdose
suppresses inhalation while xylazine prolongs exhalation, creating a respiratory cycle that collapses from both
- 📰 GPCR Buzz: August 5-11, 2024 | Top Highlights from DrGPCR University!
Check out what’s coming in September and October: Sign up for both courses now and score a 25% early
- 📰 GPCR Weekly News, January 16 to 22, 2023
Cannabinoid tolerance in S426A/S430A x beta-arrestin 2 knock-out double mutant mice.
- 📰 GPCR Weekly News, June 24 to 30, 2024
Drugs, and more Molecular glues as potential GPCR therapeutics A high-affinity, cis-on photoswitchable beta from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone Tectonic bets
- 📰 GPCR Weekly News, August 21 to 27, 2023
Molecular Insights into GPCR Function Structural bioinformatics studies of bacterial outer membrane beta-barrel
- Drug Discovery Pharmacology Principles That Turn Assays Into Real Medicines
When both disciplines collaborate effectively, pharmacology data becomes a roadmap that guides molecular
- The Hidden Cost of Ambition in Biotech Leadership
The CEO Decision Filters That Protect Both Focus and Biotech Fundraising 👉 Strategic discipline becomes
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
diabetic models have shown that although exendin-P5 induces lower insulin release compared to exendin, both
- 📰 GPCR Weekly News, August 28 to September 3, 2023
stimulates human ovarian cancer cell invasion by upregulating MMP-9 via ERK1/2 signaling CCR7 acts as both
- Therapeutic validation of an orphan G protein‐coupled receptor
GPR84 is a promising target to exploit and the investment in better tools to study its function in both
- VAMP2: a crucial player in the delivery of MOR to the synapse
In addition, VAMP2 can interact with other GPCRs, such as the beta-2 adrenergic receptor and the mu-opioid
- 📰 GPCR Weekly News, February 27 to March 5, 2023
Elucidation of a dynamic interplay between a beta-2 adrenergic receptor, its agonist, and stimulatory
- 📢 Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024
Become a Premium Member to access both courses at a reduced price.
- Why Biotech Fundraising Fails Due to Intellectual Property Gaps
Clear intellectual property builds confidence on both sides of the biotech fundraising table Why biotech
- GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures
Common mechanistic traps: Alpha-driven effects misinterpreted as beta-driven, or vice versa.
- The Hidden Burn: How Internal Misalignment Drains Your Biotech’s Runway
You pay for both. You benefit from neither.
- 📰 GPCR Weekly News, December 18 to 31, 2023
by human neutrophil expressed formyl peptide receptors GPCRs in Cardiology, Endocrinology, and Taste Beta
- Chemokine receptor-targeted drug discovery: progress and challenges
Furthermore, both chemokines and receptors can homo- and hetero-oligomerize, impacting receptor/ligand-binding
- Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling
Both BERKY and ONE-GO biosensors are engineered to detect the GTP-bound Gα subunit, serving as a proxy
- GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!
faculty members who adeptly simplify the intricacies of GPCR pharmacology for practical application in both
- Biotech Startup Failure: Why Teams Drift Off Course Without a Single Wrong Decision
Over time, this sideways motion becomes costly, both financially and organizationally. 👉 By the time



















